meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced OC (mOC) - maintenance (M)
2
pancreatic ductal adenocarcinoma
PIK3CA-related overgrowth spectrum
prostate cancer (PC)
<span style="margin-left: 0em;">immune chekpoint inhibitors</span>
<span style="margin-left: 1em;">anti-PD-(L)1</span>
<span style="margin-left: 2em;">avelumab based treatment</span>
<span style="margin-left: 3em;">avelumab plus SoC <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span>
<span style="margin-left: 2em;">nivolumab based treatment <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span>
<span style="margin-left: 0em;">poly ADP-ribose polymerase (PARP) inhibitor</span>
<span style="margin-left: 1em;">rucaparib <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span>
Select endpoint...
PFS (extension) (1)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
insufficient data
Evidence network for EEEE
rucaparib
avelumab plus SoC
nivolumab based treatment
direct evidence
network meta-analysis
comet plot
result box
odds ratio
A
B
0.5
1.5
1.0
odds ratio for A vs. B
and half 95% CI
T
vs.
C
rucaparib
avelumab plus SoC
nivolumab based treatment
rucaparib
---
NA
NA
avelumab plus SoC
NA
---
NA
nivolumab based treatment
NA
NA
---
pathologies: 246 - treatments: 855,360,719,721,720,842,642,674,1085,863
result logic
×
Study list
